DACH1: Its Role as a Classifier of Long Term Good Prognosis in Luminal Breast CancerReport as inadecuate




DACH1: Its Role as a Classifier of Long Term Good Prognosis in Luminal Breast Cancer - Download this document for free, or read online. Document in PDF available to download.

Background

Oestrogen receptor ER positive luminal tumours account for the largest proportion of females with breast cancer. Theirs is a heterogeneous disease presenting clinical challenges in managing their treatment. Three main biological luminal groups have been identified but clinically these can be distilled into two prognostic groups in which Luminal A are accorded good prognosis and Luminal B correlate with poor prognosis. Further biomarkers are needed to attain classification consensus. Machine learning approaches like Artificial Neural Networks ANNs have been used for classification and identification of biomarkers in breast cancer using high throughput data. In this study, we have used an artificial neural network ANN approach to identify DACH1 as a candidate luminal marker and its role in predicting clinical outcome in breast cancer is assessed.

Materials and methods

A reiterative ANN approach incorporating a network inferencing algorithm was used to identify ER-associated biomarkers in a publically available cDNA microarray dataset. DACH1 was identified in having a strong influence on ER associated markers and a positive association with ER. Its clinical relevance in predicting breast cancer specific survival was investigated by statistically assessing protein expression levels after immunohistochemistry in a series of unselected breast cancers, formatted as a tissue microarray.

Results

Strong nuclear DACH1 staining is more prevalent in tubular and lobular breast cancer. Its expression correlated with ER-alpha positive tumours expressing PgR, epithelial cytokeratins CK18-19 and ‘luminal-like’ markers of good prognosis including FOXA1 and RERG p<0.05. DACH1 is increased in patients showing longer cancer specific survival and disease free interval and reduced metastasis formation p<0.001. Nuclear DACH1 showed a negative association with markers of aggressive growth and poor prognosis.

Conclusion

Nuclear DACH1 expression appears to be a Luminal A biomarker predictive of good prognosis, but is not independent of clinical stage, tumour size, NPI status or systemic therapy.



Author: Desmond G. Powe , Gopal Krishna R. Dhondalay , Christophe Lemetre, Tony Allen, Hany O. Habashy, Ian O. Ellis, Robert Rees, Graham

Source: http://plos.srce.hr/



DOWNLOAD PDF




Related documents